Formulation tactics for the delivery of poorly soluble drugs

International Journal of PharmTech Research

Volumn 4, Issue 3, 2012, Pages 914-923

  Ritika, S L Harikumar ^a   Aggarwal, Geeta ^a  

^a INSTITUTE OF NANO SCIENCE AND TECHNOLOGY   (India)

Author keywords

Bioavailability; Hydrophobic drugs; Lipophilicity; Solubility

Indexed keywords

CYCLODEXTRIN; DRUG CARRIER; LIPOSOME; NIOSOME; PHARMACOSOME; PRODRUG; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ARTICLE; DISPERSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; PARTICLE SIZE;

EID: 84870211631     PISSN: 09744304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Giliyar, C, Fikstad, DT, Tyavanagimatt, S. Challenges and oppurtunities in oral delivery of poorly water soluble drugs. Drug Del. Technol. 2006; 6:57-63
2. Pouton, CW. Formulation of poorly water soluble drugs for oral administration:physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sc. 2006; 29:278-287.
3. Yu, LX. A Biopharmaceutics classification System: The scientific Basis for Biowaiver Extensions. Pharm. Res. 2002; 19:921-925
4. Lobenberg, R, Amidon, GL. Modern bioavailability, bioequivalence and biopharmaceutical classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Sci. 2000; 50:3-20
5. Liversidge, GG, Conzentino, P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995; 125:309-313.
6. Merisko, LE, Liversidge, GG, Cooper, ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003; 18:113-120.
7. Peters, K, Leitzke, S, Diederichs, JE.Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic effi cacy in murine Mycobacterium avium infection. J. Antimicrob. Chemother. 2000; 45:77-83.
8. Moschwitzer, J, Achleitner, G, Pomper, H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur. J. Pharm. Biopharm. 2004; 58:615-619.
9. Velaga, SP, Ghaderi, R, Carlfors, J. Preparation and characterization of hydrocortisone particles using a supercritical fluid extaction system. Int. J. Pharm. 2002; 231:155-166.
10. Young, TJ, Mawson, S, Johnston, KP, Henriksen, IB, Pace, GW, Mishra, AK. Rapid expansion from supercritical to aqueous solution to produce submicron suspension of water insoluble drugs. Biotechnol. Prog. 2000; 16(3):402-407
11. Hu, J, Johnston, KP, William, RO. Spray freezing into liquid (SFL) Particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur. J. Pharm. Sci. 2003; 20(3):295-303
12. Liebenberg, W, Villiers, MM, Wurster, DE, Swanepoel, E, Dekker, TG. The effect of polymorphism on powder compaction and dissolution properties of chemically equivalent oxytetracycline hydrochloride powders. Drug Dev. Ind. Pharm. 1999; 25: 1027-1033
13. Aguiar, AJ, Krc, J, Kinkel, AW, Samyn, JC. Effect of polymorphism on absorption of chloramphenicol from chloramphenicol palmitate. J. Pharm. Sci. 1967; 56:847-853
14. Suleiman, MS, Najib, NM. Isolation and physicochemical characterization of solid forms of Glibenclamide. Int. J. Pharm. 1989; 50:103-109
15. Serajuddin, ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999; 88: 1058-1066.
16. Hulsmann, S, Backensfeld, T, Keitel, S, Bodmeier, R. Melt extrusion-an alternative method for enhancing the dissolution rate of 17 β-estradiol hemihydrate. Eur. J. Pharm. Biopharm. 2000; 49:237-242.
17. Verreck, G, Six, K, Van, DMG. Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion-Part I. Int. J. Pharm. 2003; 251:165-174.
18. Rambali, B, Verreck, G, Baert, L, Massart, DL. Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Dev. Ind. Pharm. 2003; 29:641-652
19. Wang, L, Cui, F D, Sunada, H. Preparation and evaluation of solid dispersions of nitrendipine prepared with fine silica particles using the melt-mixing method. Chem. Pharm. Bull. 2006; 54:37-43.
20. Apparao, B, Shivalingam, MR, Reddy, YVK, Rao, S, Rajesh, K, Sunitha, N. Formulation and evaluation of aceclofenac solid dispersions for dissolution rate enhancement. Int. J. Pharm. Sci. Drug. Res. 2010; 2(2):146-150.
21. Sekiguchi, K, Obi, N. A comparison of the behavior of a eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 1961; 9: 866-872.
22. Bates, T R, Sequeira, J A. Bioavailability of micronized griseofulvin from corn oil-in-water emulsion, aqueous suspension, and commercial tablet dosage forms in humans. J. Pharm. Sci. 1975; 64:793-797.
23. Hansen, T, Holm, P, Rohde, M, Schultz, K. In vivo evaluation of tablets and capsules containing spray-dried o/w-emulsions for oral delivery of poorly soluble drugs. Int. J. Pharm. 2005; 293:203-211.
24. Lawrence, MJ, Rees, GD. Microemulsion-based media as novel drug delivery system. Adv. Drug. Del. Rev. 2000; 45:89-121.
25. Azeem, A, Khan, ZI, Aqil, M, Ahmad, FJ, Khar, RK, Talegaonkar S. Microemulsions as surrogate carrier for dermal drug delivery. Drug Dev. Ind. Pharm. 2009; 35:525-547
26. Araya, H, Tomita, M, Hayashi, M. The novel formulation design of O/W microemulsion for improving the gastrointestinal absorption of poorly water soluble compounds. Int. J. Pharm. 2005; 305:61-74.
27. Dixit, RP, Nagarsenkar, MS. Optimized microemulsion and solid microemulsion systems of simvastatin: characterization and in vivo evaluation. J. Pharm. Sci. 2010; 4:892-900.
28. Mistry, RB, Sheth, NS. A review: self emulsifying drug delivery system. Int. J. Pharm. Sci. 2011; 3:23-28.
29. Kuentz, M. Oral self-emulsifyng drug delivery sytems, from biopharmaceutical to technical formulation aspects. J. Drug Del. Sci. Technol. 2011; 21:17-20
30. Mullertz, A, Ogbonna, A, Ren, S. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J. Pharm. Pharmacol. 2010; in press.
31. Shukla, J B, Patel, S J. Formulation and evaluation of Self microemulsifying system of candesartan cilexetil. Int. J. Pharm. and Pharma. Sci. 2010; 4:143-146
32. Chen, H, Chang, X, Du, D, Li, J, Xu, H, Yang, X. Microemulsion based hydrogel formulation of ibuprofen for topical delivery. Int. J. Pharm. 2006; 315:52-58
33. Loftsson, T, Duchene, D. Cyclodextrins and their pharmaceutical applications. Int. J. Pharm. 2007; 329:1-11.
34. Brewster, ME, Loftsson, T. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Del. Rev. 2007; 59:645-666
35. Becket, G, Schep, L J, Tan, M Y. Improvement of the in vitro dissolution of praziquantel by complexation with α-, β-and γ -cyclodextrins. Int. J. Pharm. 1999; 179:65-71.
36. Carrier, RL, Miller, LA, Ahmed, I. The utility of cyclodextrins for enhancing oral solubility. J. Control. Release. 2007; 123:78-99.
37. Ranpise, NS, Kulkarni, NS, Mair, PD, Ranade, AN. Improvement of water solubility and in vitro dissolution rate of aceclofenac by complexation with beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin. Pharm. Dev. Tech. 2010; 15:64-69.
38. Stella, VJ, Addae, KWN. Prodrug strategies to overcome poor water solubility. Adv. Drug Del. Rev. 2007; 59(7):677-694
39. Abu, TM. Salt formation to improve drug solubility. Adv. Drug. Del. Rev. 2007;59:603-616.
40. Kavitha, D, Sowjanya, N, Panaganti, S. Pharmacosomes: An emerging vesicular system. Int. J. Pharm. Sci. Rev. Res. 2007; 5(3):168-171
41. Torchilin, VP. Structure and design of polymeric surfactant based drug delivery systems. J. Control. Release. 2001: 73;137-172.
42. Fahr, A, van Hoogevest, P, May, S. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur. J. Pharm. Sci. 2005; 26:251-265.
43. Waterhouse, DN, Madden, TD, Cullis, PR. Preparation, characterization, and biological analysis of liposomal formulations of Vincristine. Methods Enzymol. 2005; 391:40-57.
44. Van, HP, Liu, X, Fahr, A. Role of phospholipids in the oral and parenteral delivery of poorly water soluble drugs. J. Drug Del. Sci. Technol. 2011; 21:5-16
45. Van, HP, Rogue, V, Brumec, M. Instant solubilization of poorly water-soluble drugs by in-situ loading of aqueous phospholipids dispersions suitable for parenteral administration. PDA J. Pharm. Sci. Technol. 2006; 60:366-377.
46. Shen, Y, Tu, J. Preparation and Ocular Pharmacokinetics of Ganciclovir Liposomes. AAPS Journal. 2007; 9(3):E371-E377.
47. Jadon, PS, Gajbhiye, V, Jadon, RS, Gajbhiye, KR, Ganesh, N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS Pharm. Sci. Tech. 2009; 10(4): 1186-1192.
48. Semalty, A, Semalty, M, Singh, D, Rawat, MSM. Development of physicochemical evaluation of pharmacosomes of diclofenac. Acta Pharm. 2009; 59:335-344.
49. Mehnert, W, Mader, K. Solid lipid nanoparticles. Production, characterization and applications. Adv. Drug. Del. Rev. 2001; 47:165-196.
50. Luo, Y, Chen, DW, Ren, LX, Zhao, XL, Qin, J. Solid lipid nanoparticles for enhancing vinopocetine's oral bioavailability. J. Control. Release. 2009; 114:53-59
51. Li, HL, Zhao, XB, Ma, YK, Zhai, GX, Li, LB. Enhancement of gastrointestinal absorption of quercitin by solid lipid nanoparticles. J. Control. Release. 2009; 133:238-244.
52. Suresh, G, Manjunath, K, Venkateswarlu, V, Satyanarayan, V. Preparation, characterization and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS Pharm. Sci. Tech. 2007; 8(24):55-61.
53. Patravale, VB, Date, AA, Kulkarni, RM. Nanosuspensions: A promising drug delivery strategy. J. Pharm. Pharmacol. 2004; 56:827-840.
54. Keck, CM, Mulle,r RH. Drug nanocrystals of poorly soluble drugs produced by high pressurehomogenisation. Eur. J. Pharm. Biopharm. 2006; 62(1):3-16
55. Junghanns, JUAH, Muller, RH. Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomedicine. 2008; 3(3):295-310.
56. Shegokar, R, Muller, RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int. J. Pharm. 2010; 399:129-139.